8-cyclohexyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 8-cyclohexyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
• 英文别名: 8-cyclohexyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one；8-cyclohexyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
• 化学式: C₂₂H₂₇N₇O
• 分子量: 405.503
• InChiKey: VNTYBILELZJQSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  86.3
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
  申请人：——

  公开号：US20030149001A1

  公开（公告）日：2003-08-07

  The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4). 1

  这项发明提供了用于治疗细胞增殖性疾病的取代2-氨基吡啶。本发明的新化合物是cyclin-dependent激酶4 (cdk4)的有效抑制剂。
• [EN] ANTIBACTERIAL OXADIAZOLONE DERIVATIVES<br/>[FR] DÉRIVÉS D'OXADIAZOLONE ANTIBACTÉRIENS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2014108836A1

  公开（公告）日：2014-07-17

  The invention relates to antibacterial compounds of formula (I) wherein U represents CH or N; V represents CH or N, provided that at least one of U and V does not represent N; R represents H, halogen, methyl, methoxy, cyano or ethynyl; either W represents a phenyl group substituted in para position with (C1 -C3)alkyl, (C1-C3)alkoxy or (C1-C3)thioalkoxy and optionally in meta position with halogen, or W is a group having one of the formulae W1 and W2 below wherein Q is O or S and X is CH or N; and salts of such compounds.

  该发明涉及式(I)的抗菌化合物，其中U代表CH或N；V代表CH或N，前提是U和V中至少有一个不代表N；R代表H、卤素、甲基、甲氧基、氰基或乙炔基；W代表一个苯基，该苯基在对位被(C1-C3)烷基、(C1-C3)氧烷基或(C1-C3)硫代氧烷基取代，并且可选地在间位被卤素取代，或者W是具有下列式W1和W2之一的基团，其中Q为O或S，X为CH或N；以及这类化合物的盐。
• [EN] THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR AND/OR A CDK 4/6 INHIBITOR<br/>[FR] COMBINAISONS THÉRAPEUTIQUES D'UN INHIBITEUR DE LA BTK, D'UN INHIBITEUR DE LA PI3K, D'UN INHIBITEUR DE LA JAK-2 ET/OU D'UN INHIBITEUR DE LA CDK 4/6
  申请人：ACERTA PHARMA BV

  公开号：WO2016024232A1

  公开（公告）日：2016-02-18

  Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms (PI3K-γ,δ, PI3K-γ, and PI3K-δ, a Janus kinase-2 (JAK-2) inhibitor, a cyclin-dependent kinase- 4/6 (CDK4/6) inhibitor, and/or a Bruton's tyrosine kinase (BTK) inhibitor are described. In certain embodiments, the invention includes therapeutic combinations of a cyclin-dependent kinase-4/6 (CDK4/6) inhibitor and a BTK inhibitor, a PI3K-δ inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a JAK-2, PI3K-δ, and BTK inhibitor.

  描述了磷脂酰肌醇3-激酶（PI3K）抑制剂的治疗组合，包括选择性作用于γ-和δ-异构体以及同时选择γ-和δ-异构体（PI3K-γ,δ, PI3K-γ和PI3K-δ）的PI3K抑制剂，一种Janus激酶-2（JAK-2）抑制剂，一种细胞周期依赖性激酶-4/6（CDK4/6）抑制剂，和/或一种Bruton氏酪氨酸激酶（BTK）抑制剂。在某些实施例中，该发明包括细胞周期依赖性激酶-4/6（CDK4/6）抑制剂和BTK抑制剂的治疗组合，PI3K-δ抑制剂和BTK抑制剂，JAK-2和BTK抑制剂，以及JAK-2、PI3K-δ和BTK抑制剂的治疗组合。
• METHODS OF USING CELL-CYCLE INHIBITORS TO MODULATE ONE OR MORE PROPERTIES OF A CELL CULTURE
  申请人：AMGEN INC.

  公开号：US20150353542A1

  公开（公告）日：2015-12-10

  Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the addition of cell cycle inhibitors to growing cell cultures.

  提供了一种调节表达感兴趣蛋白的细胞培养物性质的方法。在各种实施方式中，该方法涉及向生长的细胞培养物中添加细胞周期抑制剂。
• [EN] 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES<br/>[FR] 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3-D]PYRIMIDIN-7-ONES
  申请人：WARNER LAMBERT CO

  公开号：WO2003062236A1

  公开（公告）日：2003-07-31

  The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 ( cdk4 ).

  本发明提供了用于治疗细胞增殖性疾病的取代的2-氨基吡啶。本发明的新化合物是cyclin-dependent kinases 4 (cdk4)的有效抑制剂。